1. Home
  2. Team
  3. Isabella Mihov

Isabella joined MVM in 2023. Prior to MVM, she led the commercial team in a digital health company, and worked as a consultant at Oliver Wyman where she advised life sciences and healthcare organisations. Isabella completed a BSc in Biotechnology and MSc in Bioinformatics at Imperial College London, and holds a Masters in Bioscience Enterprise from the University of Cambridge.

Latest news

OSSIO Raises $27.6 Million to Accelerate Its Commercial Engine as High Demand for Bio-Integrative Fixation Technology Continues
December 2, 2024
Hologic agrees to acquire Gynesonics
October 14, 2024
eXmoor Pharma Partners with Quell Therapeutics to Develop CAR-Treg Cell Therapies
September 24, 2024
Stryker agrees to acquire Vertos Medical
August 22, 2024
eXmoor Pharma’s GMP cell and gene therapy manufacturing facility receives license from MHRA
August 20, 2024
Providence Medical Technology, Inc. Announces FDA Clearance of CORUS™ Navigation Access System for Use with Medtronic’s StealthStation™ Surgical Navigation in Posterior Spinal Fusion
June 13, 2024
Nalu PNS System achieves significant and durable pain reduction, meeting the primary endpoint of the COMFORT RCT study
June 4, 2024
GT Medical Technologies, Inc. Completes Strategic Acquisition of Radioactive Seed Assets from Perspective Therapeutics, Inc.
April 15, 2024
Optinose’s XHANCE® Approved by FDA for Chronic Rhinosinusitis without Nasal Polyps
March 15, 2024
GT Medical Technologies Names Per Langoe As CEO
February 20, 2024
View all